Cargando…

Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.

The levels of tumour-associated trypsin inhibitor (TATI), CA 125 and CEA were measured in ovarian cyst fluids from 21 patients. TATI in cyst fluid was immunologically and physicochemically similar to the peptide originally isolated from the urine of a patient with ovarian cancer. Mucinous cysts cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halila, H., Huhtala, M. L., Haglund, C., Nordling, S., Stenman, U. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1987
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002139/ https://www.ncbi.nlm.nih.gov/pubmed/3117086

Ejemplares similares

Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.
por: Haglund, C., et al.
Publicado: (1986)

Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
por: Halila, H., et al.
Publicado: (1988)

Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.
por: Venesmaa, P., et al.
Publicado: (1994)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
por: Medl, M., et al.
Publicado: (1995)

Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status
por: Sjöblom, Anni, et al.
Publicado: (2021)

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
por: Haglund, C.
Publicado: (1986)

Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI
por: Kozakiewicz, Barbara, et al.
Publicado: (2016)

Concomitant Tumor Expression of EGFR and TATI/SPINK1 Associates with Better Prognosis in Colorectal Cancer
por: Koskensalo, Selja, et al.
Publicado: (2013)

The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation
por: Paju, A, et al.
Publicado: (2001)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies
por: Deng, Lin, et al.
Publicado: (2020)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

Diagnostic Utility of Combined CEA, CA15-3 and CA125 Biomarkers and Cytomorphology in Suspicious and Malignant Serosal Fluid
por: Rahemi, Zahra, et al.
Publicado: (2021)

Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis
por: Guo, Junhong, et al.
Publicado: (2017)

Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
por: Kuusela, P., et al.
Publicado: (1991)

Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.
por: Haglund, C., et al.
Publicado: (1991)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells
por: Lippolis, G, et al.
Publicado: (2013)

The Clinical Significance of CEA, CA19–9, and CA125 in Management of Appendiceal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
por: Kuusela, P., et al.
Publicado: (1987)

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer
por: Wan, Qiuhua, et al.
Publicado: (2021)

Preoperative serum levels of CEA and CA 242 in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1995)

Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge
por: Zhao, Song, et al.
Publicado: (2016)

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma
por: Wang, Wei, et al.
Publicado: (2016)

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
por: Haglund, C., et al.
Publicado: (1989)

Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis.
por: Haglund, C., et al.
Publicado: (1986)

Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer
por: Feng, Fan, et al.
Publicado: (2017)

Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection
por: Zang, Ruochuan, et al.
Publicado: (2019)

Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei
por: Liang, Lei, et al.
Publicado: (2021)

Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma
por: Fang, Tianyi, et al.
Publicado: (2019)

Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
por: Sun, Zhipeng, et al.
Publicado: (2014)

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer
por: Wang, Gangping, et al.
Publicado: (2014)

Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer
por: Luo, Hai, et al.
Publicado: (2020)

Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
por: Sinha, Seema Rani, et al.
Publicado: (2022)

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
por: Chen, Fawen, et al.
Publicado: (2018)

Prognostic Values Of Preoperative Serum CEA And CA125 Levels And Nomograms For Young Breast Cancer Patients
por: Li, Xuan, et al.
Publicado: (2019)

Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as add-on tools to ultrasound for the differentiation of ovarian from non-ovarian pelvic masses
por: Nunes Pereira, Patrick, et al.
Publicado: (2023)

Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
por: ASSMAR, Mehdi, et al.
Publicado: (2016)

High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer
por: Gaber, A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_rvq41a0mtovcrihfqs5iq4ouj7